Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized controlled trial of ZVS101e for Bietti crystalline dystrophy
CTR20244811Phase 3Active
- Sponsor
- Zhongyin Biotech
- Start
- Dec 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of ZVS101e in Bietti crystalline dystrophy (BCD), sponsored by Zhongyin Biotech. Started Dec 2024; status: active.
02
Drugs
ZVS101e
03
Conditions
Bietti crystalline dystrophy (BCD)
Beyond the preview
Go deeper on CTR20244811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244811.